This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Weigel, L. M. Articles by Tenover, F. C. Search for Related Content PubMed PubMed Citation Articles by Weigel, L. M. Articles by Tenover, F. C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2002, p. 2582-2587, Vol. 46, No. 8
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.8.2582-2587.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

DNA Gyrase and Topoisomerase IV Mutations Associated with Fluoroquinolone Resistance in Proteus mirabilis

Division of Healthcare Quality Promotion, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333

Received 18 September 2001/ Returned for modification 30 November 2001/ Accepted 8 May 2002

Mutations associated with fluoroquinolone resistance in clinical isolates of Proteus mirabilis were determined by genetic analysis of the quinolone resistance-determining region (QRDR) of gyrA, gyrB, parC, and parE. This study included the P. mirabilis type strain ATCC 29906 and 29 clinical isolates with reduced susceptibility (MIC, 0.5 to 2 µg/ml) or resistance (MIC, 4 µg/ml) to ciprofloxacin. Susceptibility profiles for ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and trovafloxacin were correlated with amino acid changes in the QRDRs. Decreased susceptibility and resistance were associated with double mutations involving both gyrA (S83R or -I) and parC (S80R or -I). Among these double mutants, MICs of ciprofloxacin varied from 1 to 16 µg/ml, indicating that additional factors, such as drug efflux or porin changes, also contribute to the level of resistance. For ParE, a single conservative change of V364I was detected in seven strains. An unexpected result was the association of gyrB mutations with high-level resistance to fluoroquinolones in 12 of 20 ciprofloxacin-resistant isolates. Changes in GyrB included S464Y (six isolates), S464F (three isolates), and E466D (two isolates). A three-nucleotide insertion, resulting in an additional lysine residue between K455 and A456, was detected in gyrB of one strain. Unlike any other bacterial species analyzed to date, mutation of gyrB appears to be a frequent event in the acquisition of fluoroquinolone resistance among clinical isolates of P. mirabilis.

This article has been cited by other articles:

• Saito, R., Sato, K., Kumita, W., Inami, N., Nishiyama, H., Okamura, N., Moriya, K., Koike, K. (2006). Role of type II topoisomerase mutations and AcrAB efflux pump in fluoroquinolone-resistant clinical isolates of Proteus mirabilis. J Antimicrob Chemother 58: 673-677 [Abstract] [Full Text]  
• Han, X. Y., Andrade, R. A. (2005). Brevundimonas diminuta infections and its resistance to fluoroquinolones. J Antimicrob Chemother 55: 853-859 [Abstract] [Full Text]  
• Gruson, D., Pereyre, S., Renaudin, H., Charron, A., Bebear, C., Bebear, C. M. (2005). In Vitro Development of Resistance to Six and Four Fluoroquinolones in Mycoplasma pneumoniae and Mycoplasma hominis, Respectively. Antimicrob. Agents Chemother. 49: 1190-1193 [Abstract] [Full Text]  
• Hurtle, W., Lindler, L., Fan, W., Shoemaker, D., Henchal, E., Norwood, D. (2003). Detection and Identification of Ciprofloxacin-Resistant Yersinia pestis by Denaturing High-Performance Liquid Chromatography. J. Clin. Microbiol. 41: 3273-3283 [Abstract] [Full Text]  
• Masselot, F., Boulos, A., Maurin, M., Rolain, J. M., Raoult, D. (2003). Molecular Evaluation of Antibiotic Susceptibility: Tropheryma whipplei Paradigm. Antimicrob. Agents Chemother. 47: 1658-1664 [Abstract] [Full Text]